Pharmacists are increasingly taking on immunization roles in their communities as advocates, facilitators, and immunizers. Between 50% and 94% of people who receive a pharmacist's recommendation to be immunized accept that recommendation. Pneumococcal diseases impose a heavy burden on the health of adults in developed and developing countries. There are sound reasons for believing that much of this burden could be reduced by widespread use of the current pneumococcal vaccine. This month's column presents a cost-benefit analysis, using both published and hypothetical figures, to compare a traditional pneumococcal vaccination program with one that uses pharmacists as advocates for pneumococcal vaccination.
|Original language||English (US)|
|Number of pages||10|
|State||Published - Jan 1 2001|
ASJC Scopus subject areas
- Pharmacology (medical)